Curcumin-enhanced chemosensitivity of FDA-approved platinum (II)-based anti-cancer drugs involves downregulation of nuclear endonuclease G and NF-κB as well as induction of apoptosis and G2/M arrest

International Journal of Food Sciences and Nutrition

Volumn 65, Issue 3, 2014, Pages 368-374

  Wang, Ying Ti ^a   Liu, Hsiao Sheng ^b,c   Su, Chun Li ^a  

^a NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Carboplatin; Chemosensitivity; Cisplatin; Curcumin; NF B; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CURCUMIN; DEOXYRIBONUCLEASE; ENDONUCLEASE G; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLANT EXTRACT; PLATINUM; PLATINUM COMPLEX;

APOPTOSIS; CELL CYCLE CHECKPOINT; CHEMISTRY; CURCUMA; DOWN REGULATION; DRUG POTENTIATION; HT 29 CELL LINE; HUMAN; METABOLISM; PHYTOTHERAPY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE CHECKPOINTS; CISPLATIN; CURCUMA; CURCUMIN; DOWN-REGULATION; DRUG SYNERGISM; ENDODEOXYRIBONUCLEASES; HT29 CELLS; HUMANS; NF-KAPPA B; ORGANOPLATINUM COMPOUNDS; PHYTOTHERAPY; PLANT EXTRACTS; PLATINUM;

EID: 84898421376     PISSN: 09637486     EISSN: 14653478     Source Type: Journal    
DOI: 10.3109/09637486.2013.871694     Document Type: Article

References (40)

1. Aggarwal BB, Harikumar KB. 2009. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 41:40-59.
2. Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, Sung B, Tharakan ST, et al. 2008. Biological activities of curcumin and its analogues (Congeners) made by man and mother nature. Biochem Pharmacol 76:1590-1611.
3. Asher GN, Spelman K. 2013. Clinical utility of curcumin extract. Altern Ther Health Med 19:20-22.
4. Boulikas T, Vougiouka M. 2003. Cisplatin and platinum drugs at the molecular level. Oncol Rep 10:1663-1682.
5. Buttner S, Carmona-Gutierrez D, Vitale I, Castedo M, Ruli D, Eisenberg T, Kroemer G, Madeo F. 2007. Depletion of endonuclease G selectively kills polyploid cells. Cell Cycle 6:1072-1076.
6. Chauhan DP. 2002. Chemotherapeutic potential of curcumin for colorec-tal cancer. Curr Pharm Des 8:1695-1706.
7. Cuomo J, Appendino G, Dern AS, Schneider E, McKinnon TP, Brown MJ, Togni S, Dixon BM. 2011. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 74:664-669.
8. Cusack Jr JC, Liu R, Baldwin Jr AS. 2000. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation. Cancer Res 60:2323-2330.
9. Fadok VA, de Cathelineau A, Daleke DL, Henson PM, Bratton DL. 2001. Loss of phospholipid asymmetry and surface exposure of phosphati-dylserine is required for phagocytosis of apoptotic cells by macro-phages and fibroblasts. J Biol Chem 276:1071-1077.
10. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, et al. 2007. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670-1676.
11. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. 2011. Molecular mechanisms of cisplatin resistance. Oncogene 31:1869-1883.
12. Goel A, Kunnumakkara AB, Aggarwal BB. 2008. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 75: 787-809.
13. Gupta SC, Kismali G, Aggarwal BB. 2013. Curcumin, a component of turmeric: from farm to pharmacy. Biofactors 39:2-13.
14. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-674.
15. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. 2008. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65: 1631-1652.
16. Howells LM, Mitra A, Manson MM. 2007. Comparison of oxaliplatin-and curcumin-mediated antiproliferative effects in colorectal cell lines. Int J Cancer 121:175-183.
17. Huang KJ, Ku CC, Lehman IR. 2006. Endonuclease G: a role for the enzyme in recombination and cellular proliferation. Proc Natl Acad Sci USA 103:8995-9000.
18. Huang XF, Luo SK, Xu J, Li J, Xu DR, Wang LH, Yan M, et al. 2008. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 111:2854-2865.
19. Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. 2004. FDA drug approval summaries: oxaliplatin. Oncologist 9:8-12.
20. Ip SW, Wu SY, Yu CC, Kuo CL, Yu CS, Yang JS, Lin ZP, et al. 2011. Induction of apoptotic death by curcumin in human tongue squamous cell carcinoma SCC-4 cells is mediated through endoplasmic reticulum stress and mitochondria-dependent pathways. Cell Biochem Funct 29: 641-650.
21. Irving GR, Karmokar A, Berry DP, Brown K, Steward WP. 2011. Curcumin: the potential for efficacy in gastrointestinal diseases. Best Pract Res Clin Gastroenterol 25:519-534.
22. Kim HJ, Hawke N, Baldwin AS. 2006. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 13:738-747.
23. Lee JC, Lee CH, Su CL, Huang CW, Liu HS, Lin CN, Won SJ. 2005. Justicidin A decreases the level of cytosolic Ku70 leading to apoptosis in human colorectal cancer cells. Carcinogenesis 26:1716-1730.
24. Li L, Ahmed B, Mehta K, Kurzrock R. 2007. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 6:1276-1282.
25. Ma D, Tremblay P, Mahngar K, Collins J, Hudlicky T, Pandey S. 2011. Selective cytotoxicity against human osteosarcoma cells by a novel synthetic C-1 analogue of 7-deoxypancratistatin is potentiated by curcumin. PLoS One 6:e28780.
26. McWhinney SR, Goldberg RM, McLeod HL. 2009. Platinum neurotox-icity pharmacogenetics. Mol Cancer Ther 8:10-16.
27. Patel BB, Majumdar AP. 2009. Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview. Nutr Cancer 61:842-846.
28. Preta G, Fadeel B. 2012. AIF and scythe (Bat3) regulate phosphatidyl-serine exposure and macrophage clearance of cells undergoing fas (APO-1)-mediated apoptosis. PLoS One 7:e47328.
29. Sagar J, Sales K, Taanman JW, Dijk S, Winslet M. 2010. Lowering the apoptotic threshold in colorectal cancer cells by targeting mitochondria. Cancer Cell Int 10:31-38.
30. Sakamoto K, Maeda S. 2010. Targeting NF-kappaB for colorectal cancer. Expert Opin Ther Targets 14:593-601.
31. Sharma RA, Gescher AJ, Steward WP. 2005. Curcumin: the story so far. Eur J Cancer 41:1955-1968.
32. Shehzad A, Lee J, Lee YS. 2013. Curcumin in various cancers. Biofactors 39:56-68.
33. Siegel R, Naishadham D, Jemal A. 2012. Cancer statistics, 2012. CA Cancer J Clin 62:10-29.
34. Vaux DL, Korsmeyer SJ. 1999. Cell death in development. Cell 96: 245-254.
35. Vyas A, Dandawate P, Padhye S, Ahmad A, Sarkar F. 2013. Perspectives on new synthetic curcumin analogs and their potential anticancer properties. Curr Pharm Des 19:2047-2069.
36. Wang S, Liu Z, Wang L, Zhang X. 2009. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol 6:327-334.
37. Wickman G, Julian L, Olson MF. 2012. How apoptotic cells aid in the removal of their own cold dead bodies. Cell Death Differ 19:735-742.
38. Wlodkowic D, Skommer J, Darzynkiewicz Z. 2012. Cytometry of apoptosis. Historical perspective and new advances. Exp Oncol 34: 255-262.
39. Yu CT, Hsu JM, Lee YC, Tsou AP, Chou CK, Huang CY. 2005. Phosphorylation and stabilization of HURP by Aurora-A: implication of HURP as a transforming target of Aurora-A. Mol Cell Biol 25: 5789-5800.
40. Zhang Y, Yuan J, Zhang HY, Simayi D, Li PD, Wang YH, Li F, Zhang WJ. 2012. Natural resistance to apoptosis correlates with resistance to chemotherapy in colorectal cancer cells. Clin Exp Med 12:97-103.